Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study

Authors: Altman, Jessica K., Zuckerman, Tsila, Koprivnikar, Jamie, McCloskey, James, Kota, Vamsi, Keng, Michael, Frankfurt, Olga, Abaza, Yasmin, Bixby, Dale L., Emadi, Ashkan, Burch, Micah, Bhatnagar, Bhavana, Luger, Selina M., Percival, Mary-Elizabeth, Wolach, Ofir, Craig, Michael, Ganzel, Chezi, Roboz, Gail, Levi, Itai, Gourevitch, Anna, Flaishon, Liat, Tessler, Shoshi, Blumberg, Chen, Gengrinovitch, Stela, Ben Yakar, Ruth, Rowe, Jacob M.

Source: In Blood Advances 26 December 2023 7(24):7494-7500

BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study

Authors: Zuckerman, Tsila, Ram, Ron, Akria, Luiza, Koren-Michowitz, Maya, Hoffman, Ron, Henig, Israel, Lavi, Noa, Ofran, Yishai, Horowitz, Netanel A., Nudelman, Olga, Tavor, Sigal, Yeganeh, Shay, Gengrinovitch, Stela, Flaishon, Liat, Tessler, Shoshi, Ben Yakar, Ruth, Rowe, Jacob M.

Source: In Blood Advances 26 November 2019 3(22):3740-3749

Efficacy outcomes in the treatment of older or medically unfit patients with acute myeloid leukaemia: A systematic review and meta-analysis

Authors: Stone, A., Zukerman, Tsila, Flaishon, Liat, Yakar, Ruth Ben, Rowe, Jacob M.

Source: In Leukemia Research July 2019 82:36-42

Invariant Chain Induces B Cell Maturation in a Process That is Independent of Its Chaperonic Activity

Authors: Matza, Didi, Lantner, Frida, Bogoch, Yoel, Flaishon, Liat, Hershkoviz, Rami, Shachar, Idit

Source: Proceedings of the National Academy of Sciences of the United States of America, 2002 Mar 01. 99(5), 3018-3023.

Access URL: https://www.jstor.org/stable/3058066

Anti-inflammatory effects of an inflammatory chemokine: CCL2 inhibits lymphocyte homing by modulation of CCL21-triggered integrin-mediated adhesions

Authors: Flaishon, Liat ^*, Hart, Gili ^*, Zelman, Einat ^*, Moussion, Christine ^*, Grabovsky, Valentin, Lapidot Tal, Guy, Feigelson, Sara, Margalit, Raanan, Harmelin, Alon, Avin-Wittenberg, Tamar, Shoseyov, David, Alon, Ronen, Girard, Jean-Philippe, Shachar, Idit

Source: In Blood 15 December 2008 112(13):5016-5025

Frontline Aspacytarabine with Venetoclax for Older/Unfit Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase 1 Study

Authors: Altman, Jessica K., Abaza, Yasmin, Keng, Michael, Maiti, Abhishek, Koprivnikar, Jamie, Tessler, Shoshi, Blumberg, Chen, Flaishon, Liat, Ben Yakar, Ruth

Source: In Blood 2 November 2023 142 Supplement 1:5970-5970

CD74 induces TAp63 expression leading to B-cell survival

Authors: Lantner, Frida, Starlets, Diana, Gore, Yael, Flaishon, Liat, Yamit-Hezi, Ayala, Dikstein, Rivka, Leng, Lin, Bucala, Richard, Machluf, Yossy, Oren, Moshe, Shachar, Idit

Source: In Blood 15 December 2007 110(13):4303-4311

PHARMACEUTICAL COMPOSITIONS COMPRISING CCL2 AND USE OF SAME FOR THE TREATMENT OF INFLAMMATION

Pharmaceutical Compositions Comprising Ccl2 and Use of Same For The Treatment of Inflammation

Efficacy and safety of aspacytarabine (BST-236) as a single-agent, first-line therapy for patients with acute myeloid leukemia unfit for standard chemotherapy.

Authors: Altman, Jessica K., Koprivnikar, Jamie, McCloskey, James K., Kota, Vamsi, Frankfurt, Olga, Emadi, Ashkan, Bixby, Dale, Burch, Micah, Levy, Moshe Yair, Luger, Selina, Zuckerman, Tsila, Bhatnagar, Bhavana, Wolach, Ofir, Ganzel, Chezi, Levi, Itai, Gourevitch, Anna, Ben Yakar, Ruth, Tessler, Shoshi, Flaishon, Liat, Rowe, Jacob

Source: Journal of clinical oncology. 39(15 suppl):7007-7007

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173214836.0x000001&indx=1&recIds=ETOCvdc_100173214836.0x000001

Method and pharmaceutical composition for treating inflammation

Method and pharmaceutical composition for treating inflammation

Expression of the chemokine receptor CCR2 on immature B cells negatively regulates their cytoskeletal rearrangement and migration

Authors: Flaishon, Liat, Becker-Herman, Shirly, Hart, Gili, Levo, Yoram, Kuziel, William A., Shachar, Idit ^*

Source: In Blood 15 August 2004 104(4):933-941

Low Levels of IFN-γ Down-regulate the Integrin-dependent Adhesion of B Cells by Activating a Pathway That Interferes with Cytoskeleton Rearrangement

Authors: Flaishon, Liat ^{‡, §, ¶}, Lantner, Frida ^{‡, §}, Hershkoviz, Rami ^‡, Levo, Yoram ^‖, Shachar, Idit ^{‡, **}

Source: In Journal of Biological Chemistry 14 December 2001 276(50):46701-46706

Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

Authors: Altman, Jessica K., Koprivnikar, Jamie, McCloskey, James K, Kota, Vamsi, Keng, Michael, Bixby, Dale L., Frankfurt, Olga, Emadi, Ashkan, Zuckerman, Tsila, Burch, Micah M., Levy, Moshe Y., Luger, Selina M., Bhatnagar, Bhavana, Wolach, Ofir, Ganzel, Chezi, Percival, Mary-Beth M., Roboz, Gail J., Craig, Michael, Levi, Itai, Gourevitch, Anna, Flaishon, Liat, Cohen, Darrel P., Tessler, Shoshi, Blumberg, Chen, Gengrinovitch, Stela, Ben Yakar, Ruth, Rowe, Jacob M.

Source: In Blood 23 November 2021 138 Supplement 1:1273-1273

Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation

Authors: Altman, Jessica K., Luger, Selina M., Frankfurt, Olga ^*, Zuckerman, Tsila, Koprivnikar, Jamie L., Kota, Vamsi, Emadi, Ashkan, Bhatnagar, Bhavana, Bixby, Dale L. ^*, Burch, Micah M., Wolach, Ofir ^*, Levi, Itai ^*, Gourevitch, Anna ^*, Ram, Ron, Flaishon, Liat, Tessler, Shoshi ^*, Gengrinovitch, Stela, Ben Yakar, Ruth ^*, Rowe, Jacob M.

Source: In Blood 5 November 2020 136 Supplement 1:9-10

This result is not displayed to guests.
Login for full access.

Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b

Authors: Altman, Jessica K., Zuckerman, Tsila, Frankfurt, Olga ^*, Luger, Selina M., Bixby, Dale L. ^*, Kota, Vamsi ^*, Burch, Micah M., Wolach, Ofir ^*, Levi, Itai ^*, Gourevitch, Anna ^*, Ram, Ron, Flaishon, Liat, Tessler, Shoshi ^*, Gengrinovitch, Stela, Ben Yakar, Ruth ^*, Rowe, Jacob M.

Source: In Blood 13 November 2019 134 Supplement 1:179-179

BST-236, a Novel Cytarabine Prodrug, Is Safer and As Effective As Cytarabine in In Vivo Leukemia Models

Authors: Tessler, Shoshi ^*, Mishalian, Inbal ^*, Peri-Naor, Ronny ^*, Gengrinovitch, Stela, Mayer, Raphael ^*, Ben Yakar, Ruth ^*, Peled, Amnon ^*, Flaishon, Liat ^*

Source: In Blood 29 November 2018 132 Supplement 1:1451-1451

This result is not displayed to guests.
Login for full access.